Avidity Biosciences announced an expected record date for a planned spin‑off, advancing its strategy to separate a business unit focused on RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). The company filed the notice via PR Newswire and indicated the corporate action is part of a broader plan to unlock value for shareholders while continuing R&D on AOC programs. The record‑date announcement sets a near‑term timeline for investors and potential stakeholders preparing for the new standalone entity. For biotech corporate strategists and capital markets teams, the move underscores continued use of spin‑outs to align specialized assets with dedicated governance and funding models.